May 31, 2024 10:58 AM EDT
News Briefing

No­var­tis shares up­dat­ed da­ta for BTK in­hibitor; Astel­las re­sub­mits BLA for can­cer drug af­ter CRL

ENDPOINTS

Plus, news about Valar Labs, Pharm­ing Group and Day One Phar­ma­ceu­ti­cals:

No­var­tis out­lines one-year da­ta for BTK in­hibitor: The drug, called remi­bru­ti­nib,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

Con­duct­ing tri­als via rou­tine clin­i­cal prac­tice: FDA ex­plains how in new draft guid­ance

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times